Third-quarter earnings season has got into full swing for UK-listed blue chips with pharmaceuticals giants AstraZeneca and Shire due to report on Thursday, along with consumer product titan Unilever.
AstraZeneca will update the market on trading on the three months to the end of September, "traditionally not a quarter when the company nudges its outlook", explained analyst Savvas Neophytou from Panmure Gordon on Wednesday.
"The new Chief Executive Officer (CEO) has been in place for three weeks now, so the market will look forward to a first interaction at the helm of AstraZeneca," Neophytou said. Nevertheless, he says not to expect a "new vision" from the frontman just yet.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The broker is forecasting revenue of $6.8bn, above the consensus estimate of $6.72bn, a pre-tax profit of $1.9bn (consensus: $1.88bn) and a statutory earnings per share of $1.19 (consensus: $1.13).
However, the market will undoubtedly be looking to new CEO Pascal Soriot for some reassurance after he announced the suspension of the company's share repurchase programme earlier this month, one of his first acts as CEO.
Neophytou said: "We have felt that the share repurchase explanation (to build up a war chest for acquisitions) would have created an unwelcome overhang in the shares. Although we do not believe the company will deviate from its well established M&A valuation criteria, having learned its lessons following the acquisition of Medimmune, the market will not be willing to give it the benefit of the doubt. With a new CEO in place, strategic needs may alter."
Thursday October 25
INTERIMS
ASOS, Stobart Group Ltd.
INTERIM DIVIDEND PAYMENT DATE
BrainJuicer Group, Inmarsat, Ladbrokes, Lupus Capital, Martin Currie Global Portfolio Trust
INTERNATIONAL ECONOMIC ANNOUNCEMENTS
Bloomberg Consumer Confidence (US) (14:45)
Continuing Claims (US) (13:30)
Durable Goods Orders (US) (13:30)
Initial Jobless Claims (US) (13:30)
M3 Money Supply (EU) (09:00)
Pending Homes Sales (US) (15:00)
Q3
AstraZeneca, Petroleum Geo Services ASA, Shire Plc, Unilever
GMS
Premier Foods
FINALS
Debenhams
IMSS
AZ Electronic Materials SA (DI), Inchcape, Kazakhmys, National Express Group
EGMS
Acer Incorporated GDR (Reg S), Datang International Power Generation Co Ltd.
AGMS
Antisoma, BHP Billiton, Go-Ahead Group, Hermes Pacific Investments, Leeds Group, Lochard Energy Group
TRADING ANNOUNCEMENTS
Mail.ru Group Ltd GDR (Reg S), Stobart Group Ltd., WPP
UK ECONOMIC ANNOUNCEMENTS
GDP (Preliminary) (09:30)
Index of Services (09:30)
FINAL DIVIDEND PAYMENT DATE
Oxford Instruments
-
State pension warning as families opting out of child benefit hits record highUp to one million parents could be losing out on £6,500 in retirement because they have opted out of receiving child benefit.
-
Barclays warns of significant rise in social media investment scamsInvestment scam victims are losing an average £14k, with 61% of those falling for one over social media. Here's how to spot one and keep your money safe
